OncoMatch/Clinical Trials/NCT06848348
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
Is NCT06848348 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Halneuron for chemotherapy induced neuropathic pain.
Treatment: Halneuron — A randomized study to determine safety and efficacy of single subcutaneous (SC) administration of HAL treatment in patients with CINP.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Must have received: taxane
Patient has received a cancer chemotherapy regimen that included taxanes and/or platinum
Must have received: platinum-based chemotherapy
Patient has received a cancer chemotherapy regimen that included taxanes and/or platinum
Cannot have received: (HAL)
Patients who have received HAL at any time prior to screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Central Recruiting Site · Sheffield, Alabama
- Central Recruiting Site · Glendale, Arizona
- Central Recruiting Site · Fair Oaks, California
- Central Recruiting Site · Fountain Valley, California
- Central Recruiting Site · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify